Minerva Neurosciences, Inc.
Data quality: 83%
NERV
Nasdaq
Manufacturing
Chemicals
$5.51
▼
$0.51
(-8.47%)
Mkt Cap: 239.96 M
Price
$5.55
Mkt Cap
239.96 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—
Quick Summary
Key Takeaways
Earnings declined -20492.68% over the past year
Negative free cash flow of -13.51 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)-20492.68%
FCF Growth (3Y)N/A
Quality
Return on Equity
N/A
ROIC-44.76%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio4.87
Interest CoverageN/A
Valuation
PE (TTM)
-0.82
Above sector avg (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.8 | -1.5 |
| P/B | — | 1.6 |
| ROE % | — | -53.5 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
Analyst Price Target
2 analysts
Hold
Current
$5.51
Target
$7.25
$7.00
$7.25
$7.50
Forecast
Forward P/E
-11.48
Forward EPS
-$0.48
Est. Revenue
0.0
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2027 |
-$0.48
-$0.48 – -$0.48
|
0.0 | 1 |
| FY2026 |
-$0.60
-$0.60 – -$0.60
|
0.0 | 1 |
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| 2026 Q2 |
-$0.18
-$0.18 – -$0.18
|
0.0 | 1 |
| 2026 Q1 |
-$0.13
-$0.13 – -$0.13
|
0.0 | 1 |
Earnings Surprises
Last 4 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| Q42025 | -$0.11 | -$0.64 | -481.8% |
| Q32025 | N/A | -$0.36 | — |
| Q22025 | -$0.90 | -$0.43 | +52.2% |
| Q12025 | -$1.07 | -$0.50 | +53.3% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | -20492.68% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -293.42 M |
| ROE | N/A | ROA | -1002.96% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -13.51 M |
| ROIC | -44.76% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 4.87 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 10.35 M | Tangible Book Value | -49.45 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.82 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -5.63% | ||
| Market Cap | 239.96 M | Enterprise Value | 227.67 M |
| Per Share | |||
| EPS (Diluted TTM) | -34.67 | Revenue / Share | N/A |
| FCF / Share | -0.31 | OCF / Share | -0.31 |
| EPS CAGR (1Y) | -18347.37% | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 4.60% |
| SBC-Adj. FCF | -14.69 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 0.0 | 0.0 | 0.0 | 41.18 M |
| Net Income | -293.42 M | 1.44 M | -30.01 M | -32.11 M | -49.91 M |
| EPS (Diluted) | -34.67 | 0.19 | -4.61 | -6.01 | -1.17 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -15.10 M | -21.85 M | -23.12 M | -25.23 M | -45.37 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 5.76 M | 11.90 M | 12.71 M | 14.65 M | 32.04 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 5,442.0 | 5,442.0 | 5,442.0 | — | 16,011.0 |
| Interest Expense | — | — | — | — | — |
| Income Tax | — | — | — | -1.80 M | -1.80 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 97.97 M | 37.14 M | 56.90 M | 55.09 M | 77.12 M |
| Total Liabilities | 233.76 M | 62.84 M | 85.36 M | 75.11 M | 69.15 M |
| Shareholders' Equity | -140.75 M | -25.69 M | -28.46 M | -20.02 M | 7.98 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 82.30 M | 21.36 M | 40.91 M | 36.09 M | 60.76 M |
| Current Assets | 83.10 M | 22.27 M | 42.00 M | 40.16 M | 62.20 M |
| Current Liabilities | 2.29 M | 2.84 M | 3.34 M | 1.38 M | 2.82 M |
{"event":"ticker_viewed","properties":{"ticker":"NERV","listing_kind":"stock","pathname":"/stocks/nerv","exchange":"Nasdaq","country":"US"}}